#Germany #CAR-T #Cologne #Cellex #ATMP

Cellex Cell Professionals Surpasses 10,000 Autologous ATMP Batches

Cellex Cell Professionals, a leading contract development and manufacturing organization (CDMO) specializing in personalized cell therapies, has recently announced a groundbreaking achievement – the production of over 10,000 autologous Advanced Therapy Medicinal Products (ATMPs). This milestone reflects the immense experience and dedication of Cellex in addressing the needs of both clinical and commercial partners in the field of innovative therapeutics.

Autologous cell therapy involves the individualized processing of cell-based treatments for patients, meaning that each batch produced is tailored specifically for a single recipient. The process includes the extraction of starting materials, manufacturing, rigorous quality control, logistics, and a stringent chain of identity protocols. As such, each batch produced by Cellex is not just a number but encapsulates a coordinated effort that is crucial for patients eagerly awaiting their treatments.

Dr. Suvi Annala, Vice President of Manufacturing at Cellex, emphasized the significance of this achievement, stating, “Every single one of these 10,000 batches was manufactured for a specific patient. Behind each of these is a coordinated chain involving sourcing, manufacturing, testing, and logistics that must run to a timeline critical for someone waiting for their treatment.”

In addition to managing the complexities of batch production, Cellex draws on its own experiences in developing CAR-T programs. The formation of AvenCell in 2021 marked an expansion for Cellex into allogeneic CAR-T therapies that are edited using CRISPR/Cas technology, further enhancing the company’s insight into the scientific, regulatory, and operational hurdles its partners face. This understanding enables Cellex to continuously refine its processes, quality systems, and operational models to better serve its partners and patients alike.

Cellex is committed to investing in the capabilities necessary to meet the evolving demands of increasingly complex cell therapy programs. This includes expanding their facilities, such as the addition of new Class B clean rooms at the Köln-Ossendorf site. Such developments ensure that Cellex can reliably produce complex cell therapies at scale, ultimately delivering them to patients who depend on these advanced treatments.

Cellex Cell Professionals has over a decade of experience in manufacturing both autologous and allogeneic products. The company supports partners from the pharmaceutical, biotechnology, and scientific sectors, guiding them from preclinical and clinical development stages to commercial manufacturing. Its comprehensive approach combines Good Manufacturing Practice (GMP) expertise with capabilities in sourcing cellular starting materials and managing supply chains.

This significant milestone not only demonstrates Cellex's operational proficiency but also highlights its commitment to leading innovation within the cell therapy landscape. As they continue to collaborate with partners to push the boundaries of what's possible in personalized medicine, Cellex remains at the forefront of delivering hope and healing to patients worldwide.

For more information about Cellex Cell Professionals and its groundbreaking work in cell therapy manufacturing, visit www.cellex.me/en.